These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17355163)

  • 1. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders.
    Ambrosioni E
    Am J Cardiovasc Drugs; 2007; 7(1):17-24. PubMed ID: 17355163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.
    Borghi C; Cicero AF
    Vasc Health Risk Manag; 2006; 2(4):341-9. PubMed ID: 17323587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions.
    Omboni S; Malacco E; Parati G
    Cardiovasc Ther; 2009; 27(4):275-88. PubMed ID: 19832845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.
    Zanchetti A; Parati G; Malacco E
    Drugs; 2006; 66(8):1107-15. PubMed ID: 16789795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Zofenopril Alone or in Combination with Hydrochlorothiazide in Patients with Kidney Dysfunction.
    Omboni S; Borghi C
    Curr Clin Pharmacol; 2019; 14(1):5-15. PubMed ID: 30360726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zofenopril: Blood pressure control and cardio-protection.
    Borghi C; Ambrosio G; Van De Borne P; Mancia G
    Cardiol J; 2022; 29(2):305-318. PubMed ID: 34622438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardioprotective role of zofenopril in hypertensive patients with acute myocardial infarction: a pooled individual data analysis of the SMILE studies.
    Borghi C; Omboni S; Reggiardo G; Bacchelli S; Degli Esposti D; Ambrosioni E;
    Blood Press; 2017 Aug; 26(4):211-219. PubMed ID: 28155333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril.
    Evangelista S; Manzini S
    J Int Med Res; 2005; 33(1):42-54. PubMed ID: 15651714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of acute myocardial infarction with angiotensin-converting enzyme inhibition: safety considerations. SMILE pilot study working party.
    Ambrosioni E; Borghi C; Magnani B
    Am J Cardiol; 1991 Nov; 68(14):101D-110D. PubMed ID: 1746414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
    Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
    Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases.
    Borghi C; Bacchelli S; Degli Esposti D; Ambrosioni E
    Expert Opin Pharmacother; 2004 Sep; 5(9):1965-77. PubMed ID: 15330734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.
    Liu X; Engelman RM; Rousou JA; Cordis GA; Das DK
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):437-43. PubMed ID: 1387799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study.
    Borghi C; Ambrosioni E;
    Am Heart J; 2007 Mar; 153(3):445.e7-14. PubMed ID: 17307427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies.
    Borghi C; Omboni S; Reggiardo G; Bacchelli S; Esposti DD; Ambrosioni E;
    BMC Cardiovasc Disord; 2018 Jun; 18(1):112. PubMed ID: 29866077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update.
    Borghi C; Omboni S
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1055-65. PubMed ID: 25098297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease.
    Buikema H
    Expert Rev Cardiovasc Ther; 2006 Sep; 4(5):631-47. PubMed ID: 17081085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats.
    García-Estañ J; Ortiz MC; O'Valle F; Alcaraz A; Navarro EG; Vargas F; Evangelista S; Atucha NM
    Clin Sci (Lond); 2006 Feb; 110(2):227-33. PubMed ID: 16197366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation.
    Borghi C; Bacchelli S; Esposti DD; Bignamini A; Magnani B; Ambrosioni E
    Am J Hypertens; 1999 Jul; 12(7):665-72. PubMed ID: 10411363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice.
    de Nigris F; D'Armiento FP; Somma P; Casini A; Andreini I; Sarlo F; Mansueto G; De Rosa G; Bonaduce D; Condorelli M; Napoli C
    Int J Cardiol; 2001 Dec; 81(2-3):107-15; discusssion 115-6. PubMed ID: 11744122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.